Compare SLGN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | CRSP |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.0B |
| IPO Year | 1994 | 2016 |
| Metric | SLGN | CRSP |
|---|---|---|
| Price | $42.39 | $59.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $52.78 | ★ $70.29 |
| AVG Volume (30 Days) | 1.4M | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $4,489,927,000.00 | $289,590,000.00 |
| Revenue This Year | $4.99 | $807.72 |
| Revenue Next Year | $2.20 | $172.52 |
| P/E Ratio | $31.39 | ★ N/A |
| Revenue Growth | 0.92 | ★ 9169.85 |
| 52 Week Low | $35.68 | $44.12 |
| 52 Week High | $49.41 | $78.48 |
| Indicator | SLGN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 67.33 |
| Support Level | $41.98 | $50.17 |
| Resistance Level | $43.74 | $60.10 |
| Average True Range (ATR) | 1.01 | 2.32 |
| MACD | -0.00 | 0.91 |
| Stochastic Oscillator | 69.89 | 78.95 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.